Tebentafusp improves OS: A First in Metastatic Uveal Melanoma Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chemotherapy | Eye Cancers | Hematology | Immunotherapy | Melanoma | Skin Cancer | Uveal Melanoma